HSP90AA1 and central nervous system cancer: HSP90 inhibition might be a novel strategy for advanced papillary renal cell carcinoma [173], metastatic triple-negative breast cancer [174], pancreatic carcinoma [175], prostate cancer [176], and glioma [177] treatment.